The FDA cleared Ionis Pharmaceuticals’ first disease-modifying therapy for Alexander disease, approving Zanvastro for children and adults following results from a pivotal trial. The primary efficacy readout centered on walking speed—a common motor-function metric in neurologic disorders—with treated patients maintaining performance while the control group declined.